Department of Public Health, Shihezi University School of Medicine, Shihezi, Xinjiang 832000, China.
The First Affiliated Hospital of Shihezi University Medical College, Shihezi, Xinjiang 832000, China.
Mediators Inflamm. 2019 May 5;2019:4756295. doi: 10.1155/2019/4756295. eCollection 2019.
This study involved the development of a predictive 5-year morbidity nomogram for cardiovascular diseases (CVD) in Xinjiang Kazakhs based on cytokine levels.
The nomogram was based on a baseline survey of the town of Nalati in the Kazakh Autonomous Prefecture of Xinjiang from 2009 to 2013. By 2016, we had monitored 1508 people for a median time of 5.17 years and identified CVD events in the study population by collecting case information from local hospitals. The study population was divided into the training ( = 1005) and validation cohorts ( = 503) in a 2 : 1 ratio. The area under the receiver operating characteristic curve (AUC) was used to verify the predictive accuracy of the nomogram. The result was assessed in a validation cohort.
At the end of the study, the incidence of CVD in Xinjiang Kazakhs was found to be 11.28%. We developed a new nomogram to predict the 5-year incidence of CVD based on age, interleukin-6 (IL-6), and adiponectin (APN) levels, diastolic blood pressure, and dyslipidemia. The AUC for the predictive accuracy of the nomogram was 0.836 (95% confidence interval: 0.802-0.869), which was higher than that for IL-6 and APN. These results were supported by validation studies.
The nomogram model can more directly assess the risk of CVD in Kazakhs and can be used for CVD risk assessment.
本研究基于细胞因子水平,为新疆哈萨克人群开发了一种预测心血管疾病(CVD)5 年发病率的列线图。
该列线图基于 2009 年至 2013 年新疆哈萨克自治州那拉提镇的基线调查。到 2016 年,我们监测了 1508 人,中位随访时间为 5.17 年,并通过收集当地医院的病例信息,确定了研究人群中的 CVD 事件。研究人群按 2:1 的比例分为训练队列(n = 1005)和验证队列(n = 503)。采用受试者工作特征曲线下面积(AUC)验证列线图的预测准确性。在验证队列中评估了结果。
研究结束时,发现新疆哈萨克人群 CVD 的发病率为 11.28%。我们开发了一种新的列线图,用于预测基于年龄、白细胞介素 6(IL-6)和脂联素(APN)水平、舒张压和血脂异常的 5 年 CVD 发生率。该列线图预测准确性的 AUC 为 0.836(95%置信区间:0.802-0.869),高于 IL-6 和 APN。验证研究支持了这些结果。
该列线图模型可以更直接地评估哈萨克人群 CVD 的风险,并可用于 CVD 风险评估。